Sight Sciences Inc
$ 5.18
-1.33%
25 Feb - close price
- Market Cap 277,577,000 USD
- Current Price $ 5.18
- High / Low $ 5.29 / 5.07
- Stock P/E N/A
- Book Value 1.23
- EPS -0.90
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.58 %
- 52 Week High 9.24
- 52 Week Low 2.03
About
Sight Sciences Inc. (SGHT) is an innovative medical technology firm dedicated to revolutionizing the treatment of eye diseases through both surgical and non-surgical interventions. The company's flagship products focus on improving outcomes for conditions such as glaucoma, aligning with its mission to enhance patient care in ophthalmology. Backed by a strong intellectual property portfolio and an expanding distribution network, Sight Sciences is poised for considerable growth, addressing the rising demand for effective and minimally invasive therapies in the eye care market. As the company continues to lead in ophthalmic advancements, it represents a compelling opportunity for institutional investors seeking exposure to the evolving healthcare landscape.
Analyst Target Price
$9.35
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-04-30 | 2025-03-05 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-03-07 | 2023-11-07 | 2023-08-03 | 2023-05-04 | 2023-03-13 |
| Reported EPS | -0.16 | -0.23 | -0.28 | -0.23 | -0.22 | -0.25 | -0.33 | -0.22 | -0.27 | -0.3 | -0.35 | -0.35 |
| Estimated EPS | -0.26 | -0.26 | -0.28 | -0.176 | -0.21 | -0.3 | -0.28 | -0.32 | -0.32 | -0.34 | -0.39 | -0.42 |
| Surprise | 0.1 | 0.03 | 0 | -0.054 | -0.01 | 0.05 | -0.05 | 0.1 | 0.05 | 0.04 | 0.04 | 0.07 |
| Surprise Percentage | 38.4615% | 11.5385% | 0% | -30.6818% | -4.7619% | 16.6667% | -17.8571% | 31.25% | 15.625% | 11.7647% | 10.2564% | 16.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.16 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SGHT
2026-02-18 20:57:36
Sight Sciences, Inc., an eyecare technology company, announced it will release its fourth quarter and full year 2025 financial results after the market closes on March 4, 2026. This will be followed by a conference call at 1:30 p.m. Pacific Time to discuss the results, accessible via webcast. The company focuses on innovative, minimally invasive solutions for common eye diseases like glaucoma and dry eye.
2026-02-18 20:57:36
Sight Sciences, Inc. (Nasdaq: SGHT) announced it will report its fourth quarter and full year financial results for 2025 after market close on Wednesday, March 4, 2026. The company's management will hold a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss these results, with a webcast available on their investors page. Sight Sciences is an eyecare technology company specializing in innovative solutions for prevalent eye diseases like glaucoma and dry eye disease.
2026-02-06 19:28:20
Sight Sciences, Inc. has extended its headquarters lease in Menlo Park, California, for an additional 26 months, from November 2026 to December 2028, with an initial rent abatement period. The medical device company, valued at $340 million, will resume monthly base rent in January 2027, with incremental increases throughout the lease term. This decision follows recent positive financial performance and analyst upgrades for Sight Sciences.
2026-02-05 05:57:36
Sight Sciences has extended its headquarters lease agreement for its Menlo Park office space until December 31, 2028, with a defined rent escalation schedule. This update comes despite a "Sell" rating from analysts with a $6.00 price target and a "Neutral" assessment from TipRanks' AI Analyst due to weak financial performance, though improved guidance and positive reimbursement progress offer some support.
2026-02-04 07:44:33
Sight Sciences, Inc. (NASDAQ:SGHT) has received a "Moderate Buy" consensus rating from the nine brokerages covering the firm, with an average 12-month price target of $8.30. The company recently surpassed quarterly earnings estimates, reporting -$0.16 EPS against an expected -$0.26, and generated $19.91 million in revenue. Despite this, the company remains unprofitable, and notable insider selling activity has occurred, with the CEO and CTO selling shares in January.
2026-02-04 07:29:04
Sight Sciences, Inc. has extended its headquarters lease in Menlo Park, California, for an additional 26 months, running from November 2026 to December 2028. The agreement includes a rent abatement period for November and December 2026, followed by escalating monthly rent payments. This decision follows recent positive financial news for the medical device company, including an expected 7% revenue increase for Q4 2025 and analyst upgrades.
